Evidence map›Paper›PMID 23382809›Full record

SynthesisPloS one2013

BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies.

Chun Xu, Nagesh Aragam, Xia Li, Erika Cynthia Villla, Liang Wang, David Briones, Leonora Petty, Yolanda Posada, Tania Bedard Arana, Grace Cruz and 5 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Chun XuTexas Tech University Health Sciences Center, Paul L. Foster School of Medicine, Department of Psychiatry, El Paso, Texas, United States of America. chun.xu@ttuhsc.edu
Nagesh Aragam
Xia Li
Erika Cynthia Villla
Liang Wang
David Briones
Leonora Petty
Yolanda Posada
Tania Bedard Arana
Grace Cruz
ChunXiang Mao
Cynthia Camarillo
Brenda Bin Su
Michael A Escamilla
KeSheng Wang
Texas Tech University · USEast Tennessee State University · USTexas Tech University Health Sciences Center · USUniversity of Toronto · CAHarbin Medical University · CNThe University of Texas at El Paso · USWalden University · US

Funding

MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059571 · NIMH · UNIVERSITY OF CHICAGO · PI GEJMAN, PABLO V. · 1999 to 2007
$8.0M
A Genome-Wide Association Study of SchizophreniaU01MH079469 · NIMH · NORTHSHORE UNIVERSITY HEALTHSYSTEM · PI GEJMAN, PABLO V. · 2007 to 2009
$4.4M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH060879 · NIMH · WASHINGTON UNIVERSITY · PI CLONINGER, C. ROBERT · 1999 to 2006
$2.7M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059586 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SILVERMAN, JEREMY M. · 1999 to 2006
$1.9M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH061675 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI LEVINSON, DOUGLAS FREDERICK · 1999 to 2007
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059587 · NIMH · EMORY UNIVERSITY · PI AMIN, FAROOQ · 1999 to 2006
$1.8M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059565 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 1999 to 2006
$1.7M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059588 · NIMH · UNIVERSITY OF QUEENSLAND · PI MOWRY, BRYAN JOHN · 1999 to 2006
$1.4M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH060870 · NIMH · UNIVERSITY OF CALIFORNIA IRVINE · PI BYERLEY, WILLIAM · 1999 to 2006
$1.3M
Genome-wide Association Study of SchizophreniaU01MH079470 · NIMH · STANFORD UNIVERSITY · PI LEVINSON, DOUGLAS FREDERICK · 2007 to 2009
$1.1M
MOLECULAR GENETICS OF SCHIZOPHRENIAR01MH059566 · NIMH · UNIVERSITY OF IOWA · PI BLACK, DONALD W. · 1999 to 2006
$925k
Molecular Genetics of SchizophreniaR01MH067257 · NIMH · LSU HEALTH SCIENCES CENTER · PI BUCCOLA, NANCY G · 2003 to 2007
$692k
NIMH NIH HHS R01 MH059565NIMH NIH HHS R01 MH059566NIMH NIH HHS R01 MH059571NIMH NIH HHS R01 MH059586NIMH NIH HHS R01 MH059587NIMH NIH HHS R01 MH059588NIMH NIH HHS R01 MH060870NIMH NIH HHS R01 MH060879NIMH NIH HHS R01 MH061675NIMH NIH HHS R01 MH067257NIMH NIH HHS R01 MH59565NIMH NIH HHS R01 MH59571NIMH NIH HHS R01 MH59587NIMH NIH HHS R01 MH59588NIMH NIH HHS R01 MH67257NIMH NIH HHS U01 MH046276NIMH NIH HHS U01 MH046289NIMH NIH HHS U01 MH046318NIMH NIH HHS U01 MH079469NIMH NIH HHS U01 MH079470NIMH NIH HHS U01 MH59566NIMH NIH HHS U01 MH59586NIMH NIH HHS U01 MH60870NIMH NIH HHS U01 MH60879NIMH NIH HHS U01 MH61675NIMH NIH HHS U01 MH79469NIMH NIH HHS U01 MH79470
6 · The paper itself

Abstract

Schizophrenia is a chronic and debilitating psychiatric condition affecting slightly more than 1% of the population worldwide and it is a multifactorial disorder with a high degree of heritability (80%) based on family and twin studies. Increasing lines of evidence suggest intermediate phenotypes/endophenotypes are more associated with causes of the disease and are less genetically complex than the broader disease spectrum. Negative symptoms in schizophrenia are attractive intermediate phenotypes based on their clinical and treatment response features. Therefore, our objective was to identify genetic variants underlying the negative symptoms of schizophrenia by analyzing two genome-wide association (GWA) data sets consisting of a total of 1,774 European-American patients and 2,726 controls. Logistic regression analysis of negative symptoms as a binary trait (adjusted for age and sex) was performed using PLINK. For meta-analysis of two datasets, the fixed-effect model in PLINK was applied. Through meta-analysis we identified 25 single nucleotide polymorphisms (SNPs) associated with negative symptoms with p<5×10(-5). Especially we detected five SNPs in the first two genes/loci strongly associated with negative symptoms of schizophrenia (P(meta-analysis)<6.22×10(-6)), which included three SNPs in the BCL9 gene: rs583583 showed the strongest association at a P(meta-analysis) of 6.00×10(-7) and two SNPs in the C9orf5 (the top SNP is rs643410 with a p = 1.29 ×10(-6)). Through meta-analysis, we identified several additional negative symptoms associated genes (ST3GAL1, RNF144, CTNNA3 and ZNF385D). This is the first report of the common variants influencing negative symptoms of schizophrenia. These results provide direct evidence of using of negative symptoms as an intermediate phenotype to dissect the complex genetics of schizophrenia. However, additional studies are warranted to examine the underlying mechanisms of these disease-associated SNPs in these genes.

Indexed as

Genome-Wide Association StudyAdolescentAdultAgedAged, 80 and overFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMembrane ProteinsMiddle AgedNeoplasm ProteinsPhenotypePolymorphism, Single NucleotideSchizophreniaBCL9 protein, humanMembrane ProteinsNeoplasm ProteinsTMEM245 protein, humanTranscription Factors

Identifiers

PMID23382809
PMCPMC3558516
OpenAlexW2028017622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.